Lucid Diagnostics price target lowered to $2.50 from $3 at BTIG

BTIG lowered the firm’s price target on Lucid Diagnostics to $2.50 from $3 and keeps a Buy rating on the shares. The firm updated its model following Lucid’s Q3 results, where the company beat estimates on revenue, volumes, and ASPs, helped by charges to its revenue cycle management.